Compare BridgeBio Pharma Inc (BBIO) vs Etsy Inc (ETSY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BridgeBio Pharma Inc vs Etsy Inc — how do they compare? BridgeBio Pharma Inc trades at $83.9 (market cap $16.61B), while Etsy Inc trades at $79.73 (market cap $7.38B). The key difference: BridgeBio Pharma Inc is far larger — about 2.3× Etsy Inc's market cap. Which is the better fit depends on your goals.
| BBIO | ETSY | |
|---|---|---|
Market Cap | $16.61B | $7.38B |
Sector | Health | Consumer Cyclical |
52-Week High | $90.17 | $86.47 |
52-Week Low | $47.29 | $44.05 |
Enterprise Value | $18.16B | $9.33B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BridgeBio Pharma (BBIO) trades at $84.48, up 2.03% with bullish technical signals from moving averages. Despite strong revenue growth from $222M in 2024 to $502M in 2025, the company reports significant losses with a -144.39% net margin. Recent FDA acceptance for encaleret in ADH1 and Attruby's commercial expansion in ATTR-CM provide growth catalysts, though cash flow remains negative at -$111M in 2025.
The stock presents high-risk growth potential with 88% analyst buy ratings and $102.20 consensus target, but faces substantial execution risks from ongoing losses and $1.72B debt load. Success hinges on pipeline approvals and Attruby's market penetration, making it suitable for risk-tolerant investors betting on biotech breakthroughs.
ETSY trades at $85.55, up 4.0% over 24 hours, with a bullish technical signal and consistent earnings beats in recent quarters. The company reported Q2 2026 EPS of $0.98, exceeding expectations, and announced a $2 billion share repurchase program alongside a 12% workforce reduction to boost efficiency. Revenue growth remains stable at $2.9 billion for 2026, though net income margins have moderated from prior years.
Outlook is positive with raised 2026 guidance and AI-driven marketplace improvements, but risks include high debt levels and competitive pressures. Analysts are evenly split between Buy and Hold ratings, with a consensus price target of $85.71, suggesting limited near-term upside from current levels.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About BridgeBio Pharma Inc
BridgeBio Pharma Inc is involved in identifying advance transformative medicines to treat patients who suffer from Mendelian diseases, which are diseases that arise from defects in a single gene, and cancers with clear genetic drivers. Its product pipeline categories include Mendelian, Genetic Dermatology, Oncology, and Gene therapy.
Read more on BBIO →About Etsy Inc
Etsy operates a top-10 e-commerce marketplace operator in the U.S. and the U.K., with sizable operations in Germany, France, Australia, and Canada. The firm dominates an interesting niche, connecting buyers and sellers through its online market to exchange vintage and craft goods. With $13.5 billion in 2021 consolidated gross merchandise volume, the firm has cemented itself as one of the largest players in a quickly growing space, generating revenue from listing fees, commissions on sold items, advertising services, payment processing, and shipping labels. As of the end of 2021, the firm connected more than 96 million buyers and more than 7.5 million sellers on its marketplace properties: Etsy, Reverb (musical equipment), Elo7 (crafts in Brazil), and Depop (clothing resale).
Read more on ETSY →
